Belatacept in Heart Transplantation

Exclusion Criteria67

• Study entry
• Candidate for multiple solid organ or tissue transplants
• Prior history of any organ, tissue, or cellular transplant
• Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period
• History of severe allergic and/or anaphylactic reactions to humanized or murine monoclonal antibodies
• Known hypersensitivity to NULOIX (belatacept) or ORENCIA (Abatacept)
• Previous treatment with NULOIX (belatacept) or ORENCIA (Abatacept)
• Epstein Barr Virus (EBV) seronegative or indeterminant
• Human Immunodeficiency Virus (HIV) positive
• Hepatitis B surface antigen positive
• Hepatitis B core antibody positive
• Hepatitis C virus antibody (HCV Ab+) and hepatitis C virus (HCV) Polymerase Chain Reaction (PCR) positive patients
• Patients with active Tuberculosis (TB) in the past 2 years, whether or not it was adequately treated; patients with documented treatment of active TB greater than 2 years ago will be allowed to participate if there is documentation of adequate treatment according to locally accepted clinical practice
• Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must have completed appropriate therapy for LTBI (https://www.cdc.gov/tb/topic/treatment/ltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant
• Positive serology for T. cruzi or known/suspected history of Chagas disease
• Participants currently or formerly residing in regions of the US that are highly endemic for coccidiomycosis will undergo serological testing, as per the site's standard of care. Participants with positive serology who have previously been fully treated, will be permitted to participate pending full treatment, and then require prophylaxis as further outlined in Section 7 for the duration of the study. Participants with negative serology who reside in regions where coccidiomycosis is endemic are eligible for enrollment only if they receive prophylaxis for the duration of the study. Endemic regions are determined by site based on local standard of care
• Findings on pre-transplant or pre-randomization chest x-ray or CT scan suggestive of fungal infection where an alternative etiology is not identified. Participants with a history of positive serologies for histoplasmosis or blastomycosis, performed for clinical indications will be permitted to participate if they have a normal chest x-ray or CT scan but require prophylaxis
• Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections
• Current white blood cell (WBC) count <3.0 or an absolute neutrophil count (ANC) of less than 1500 cells/mm\^3 or recurrent leukopenia that is likely to necessitate immunosuppression reduction after transplant, as determined by the site PI
• History of active inflammatory bowel disease, chronic diarrhea, or malabsorption
• History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate
• History of AL amyloidosis
• Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri-transplant period
• Patients who i) have undergone desensitization, ii) are undergoing or are planned to undergo desensitization, or iii) are intended to receive therapeutic interventions that are used for the purpose of desensitization prior to transplant
• Pretransplant Calculated Panel Reactive Antibody (cPRA) > 50% as defined by local site practices
• The use of immunosuppressive biologics within 1 month prior to transplant is not permitted. Non-immunosuppressive biologics such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors must be stopped at the time of transplant
• Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period
• The intended use of high dose (>= 2g/kg) intravenous immunoglobulin before or at the time of transplant or before study drug administration
• A personal history of severe hypogammaglobulinemia (<300mg/dL)
• Intent to give the patient a live vaccine within 30 days prior to randomization
• Use or intended use of other investigational drugs after transplant
• Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the potential participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
• Randomization
• Recipient of multiple solid organ or tissue transplants
• Prior history of any organ, tissue, or cellular transplant
• Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period
• History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies
• Known hypersensitivity to Belatacept (NULOJIX) or Abatacept (ORENCIA)
• Previous treatment with Belatacept (NULOJIX) or Abatacept (ORENCIA)
• Epstein Barr Virus (EBV) seronegative or indeterminant (recipient must be seropositive for VCA IgG and EBNA IgG)
• HIV positive patient
• Hepatitis B surface antigen positive patient
• Hepatitis B core antibody positive patient
• Hepatitis B negative transplant recipient that received a transplant from a Hepatitis B core antibody positive donor
• Hepatitis C virus antibody (HCV Ab+) and HCV PCR positive patients
• Recipient of allograft from a hepatitis C virus nucleic acid test (NAT) positive donor
• Patients with a previous history of active Tuberculosis (TB) in the past 2 years, whether or not it was adequately treated; patients with documented treatment of active TB greater than 2 years ago will be allowed to participate if there is documentation of adequate treatment according to locally accepted clinical practice
• Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must complete appropriate therapy for LTBI (https://www.cdc.gov/tb/topic/treatment/ltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant
• Positive serology for T. cruzi or known/suspected history of Chagas disease
• Participants currently or formerly residing in regions of the US that are highly endemic for coccidiomycosis will undergo serological testing, as per the site's standard of care. Participants with positive serology who have previously been fully treated, will be permitted to participate but require prophylaxis as further outlined in Section 7 of the protocol for the duration of the study. Participants with negative serology who reside in regions where coccidiomycosis is endemic are eligible for enrollment only if they receive prophylaxis for the duration of the study. Endemic regions are determined by site based on local standard of care
• Findings on pre-transplant or pre-randomization chest x-ray or CT scan suggestive of fungal infection where an alternative etiology is not identified. Participants with a history of positive serologies for histoplasmosis or blastomycosis, performed for clinical indications, will be permitted to participate if they have a normal chest x-ray or CT scan but require prophylaxis as further outlined in Section 7 of the protocol
• Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections
• Current white blood cell (WBC) count <3.0 or an absolute neutrophil count (ANC) of less than 1500 cells/mm\^3 or recurrent leukopenia that is likely to necessitate immunosuppression reduction after transplant, as determined by the site PI
• CMV high risk mismatch (D+/R-)
• History of active inflammatory bowel disease, chronic diarrhea, or malabsorption
• History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate
• History of AL amyloidosis
• Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri-transplant period
• Patients who have undergone desensitization or received therapeutic interventions that are used for the purpose of desensitization prior to transplant
• cPRA > 50% at the time of transplant or any donor specific antibodies before or at the time of transplant as determined by local site practices
• Patients who have been treated with immunosuppressive biologics within 1 month prior to transplant (non-immunosuppressive biologics must have been stopped at the time of transplant)
• Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period
• Patients who are administered or intended to be administered high dose (>=2g/kg) intravenous immunoglobulin in the immediate post-transplant period
• A personal history of severe hypogammaglobulinemia (<300mg/dL)
• Receipt of a live vaccine within 30 days prior to randomization
• Intent to use any other investigational drugs after transplantation
• Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study